Neurology and Therapy最新文献

{"title":"Network Meta-analysis of Randomized Controlled Trials Assessing Neuromodulation Therapies for Painful Diabetic Neuropathy.","authors":"Li Li, Xueqin Luo, Yong Liu, Yongjie Jiang, Yankun Chen, Yangmei Chen, Jinping Wang","doi":"10.1007/s40120-025-00759-1","DOIUrl":"https://doi.org/10.1007/s40120-025-00759-1","url":null,"abstract":"<p><strong>Introduction: </strong>Neuromodulation therapies (including non-invasive and invasive neuromodulation) are being used to treat painful diabetic neuropathy (PDN).</p><p><strong>Methods: </strong>A systematic search of the PubMed, Embase, Cochrane Library, Web of Science, and Scopus databases was conducted, from their inception until 1 October 2024, to identify randomized controlled trials (RCTs) on neuromodulation therapies for PDN. Data were collected on pain intensity of various adjunctive therapies for PDN, including transcutaneous electrical nerve stimulation (TENS), percutaneous electrical nerve stimulation, repetitive transcranial magnetic stimulation, pulsed electromagnetic field therapy, spinal cord stimulation (SCS), transcranial direct current stimulation, frequency rhythmic electrical modulation system, mesodiencephalic modulation, and sham.</p><p><strong>Results: </strong>The data from an aggregate of 12 separate studies, comprising a total sample size of 922 participants, was subject to analysis. All seven neuromodulation therapies exhibited better outcomes in pain intensity compared to the Sham intervention, with TENS achieving the highest ranking, followed by SCS. At the final follow-up time point, statistically significant reductions in pain intensity (vs. Sham) was only observed for SCS.</p><p><strong>Conclusion: </strong>The results of this network meta-analysis should facilitate the development of clinical guidance and enhance the decision-making process for both patients and healthcare professionals, thereby identifying the most appropriate PDN treatment options.</p><p><strong>Trial registration: </strong>PROSPERO: CRD42024597208.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS.","authors":"Aurora Zanghì, Paola Sofia Di Filippo, Carlo Avolio, Emanuele D'Amico","doi":"10.1007/s40120-025-00736-8","DOIUrl":"https://doi.org/10.1007/s40120-025-00736-8","url":null,"abstract":"<p><strong>Introduction: </strong>Cognitive dysfunction represents a major burden in multiple sclerosis (MS). The impact on cognitive outcomes of ozanimod in real-world settings remains to be fully elucidated.</p><p><strong>Methods: </strong>In this single-center observational study, we evaluated cognitive performance in 67 patients with MS (74.6% female) receiving ozanimod (mean treatment duration 17.7 ± 3.0 months). Cognitive assessment was performed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery, comprising Symbol Digit Modalities Test (SDMT), California Verbal Learning Test-II (CVLT-II), and Brief Visuospatial Memory Test-Revised (BVMT-R) collected at different time points.</p><p><strong>Results: </strong>Analysis suggested significant improvement in SDMT Z-scores (mean improvement 0.337, SD 0.638; Cohen's d = 0.42, p = 0.00031). Baseline SDMT Z-score emerged as the sole significant predictor of cognitive change (coefficient - 0.345, p < 0.001), accounting for 32.4% of variance. CVLT-II and BVMT-R scores remained stable across time points.</p><p><strong>Conclusions: </strong>This real-world study suggests that ozanimod treatment is associated with significant improvement in information processing speed, independent of traditional prognostic factors. These findings complement existing clinical trial data and warrant further investigation through larger, multicenter studies with extended follow-up periods to validate these cognitive benefits.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Modified Functional Status Questionnaire for Assessing Patients with Parkinson's Disease Psychosis Treated with Pimavanserin: A Post Hoc Analysis.","authors":"Virgilio G H Evidente, Lambros Chrones, Ratna Revankar, Dilesh Doshi, Victor Abler, Nazia Rashid","doi":"10.1007/s40120-025-00757-3","DOIUrl":"https://doi.org/10.1007/s40120-025-00757-3","url":null,"abstract":"<p><strong>Introduction: </strong>Over half of patients with Parkinson's disease experience psychosis (PDP) symptoms over the course of their disease. In addition to significantly impacting patients' health-related quality of life and cognitive abilities, these symptoms impact patients' activities of daily living (ADLs) and overall functional status. Clinical assessment of how psychosis impacts these measures is crucial; however, few studies have assessed functional status among patients with PDP. A previous phase 4 study assessing the impact of pimavanserin on ADLs in patients with PDP demonstrated that a modified version of the Functional Status Questionnaire (mFSQ) could be used for this purpose. This post hoc analysis aimed to demonstrate the utility of the mFSQ as a patient-reported outcomes tool and to expand on initial study findings by showing the impact of pimavanserin on ADLs and functional status for each mFSQ subscale.</p><p><strong>Methods: </strong>An analysis of mFSQ data was conducted on patients with PDP treated with pimavanserin. This analysis evaluated the least-squares mean (LSM) change from baseline to week 16 on the mFSQ by subscale (basic ADL, intermediate ADL, psychological function, quality of interaction, and social activity). Pearson's correlation was used to assess the relationship between results from the mFSQ and the well-established Schwab and England ADL scale.</p><p><strong>Results: </strong>In this assessment (n = 29), treatment with pimavanserin was associated with improvements on all 5 domains of the mFSQ, highlighting a broad improvement in ADLs and function. The greatest LSM (SE) improvement was seen in the social activity subscale [25.8 (7.52); 95% CI 10.2-41.5; p = 0.0026]. The mFSQ results demonstrated positive correlations with patient- and caregiver-rated Schwab and England ADL scales.</p><p><strong>Conclusion: </strong>This analysis provides additional information about the impact of treatment with pimavanserin on specific mFSQ subscales. Additionally, the mFSQ was significantly correlated with the patient- and the caregiver-rated Schwab and England ADL scales.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Future Amyotrophic Lateral Sclerosis Medicines by Incorporating The Patient Voice Into Patient-Centered Holistic Measurement Strategies for Clinical and Real-World Studies: Results from Targeted Literature Reviews.","authors":"Diana Rofail, Michael Chladek, Betsy Williams, Nick Patel, William B Nowell, Stella Karantzoulis, Oren Levy","doi":"10.1007/s40120-025-00740-y","DOIUrl":"https://doi.org/10.1007/s40120-025-00740-y","url":null,"abstract":"<p><strong>Introduction: </strong>This analysis sought to understand the patient experience in amyotrophic lateral sclerosis (ALS) and to assess whether commonly used clinical outcome assessments (COAs) reliably and validly capture that experience.</p><p><strong>Methods: </strong>Two targeted literature reviews were conducted to identify and describe key concepts potentially important to patients (signs, symptoms, impacts), and identify commonly used COAs in ALS. Insights gained were used to map target COAs to concepts identified as potentially relevant to patients and their caregivers. COAs of interest were further examined to evaluate evidence of their validity and reliability within ALS.</p><p><strong>Results: </strong>Forty-three articles were identified for concept extraction. Signs and symptoms were identified across multiple themes: motor; non-motor; respiratory; cognitive; and behavioral. Patient impacts were identified across multiple themes: physical; functional; emotional; social; and other aspects of well-being. Caregiver impacts were identified across four themes: general; emotional; social; and physical. Of 236 unique COAs identified, 6 were found to provide the greatest coverage of potentially important concepts. Closer examination of these showed some evidence gaps supporting content validity and/or psychometric properties.</p><p><strong>Conclusions: </strong>Several concepts related to ALS were identified that are relevant to patients in their daily lives. We identified and reviewed COAs commonly used in assessing these concepts, and found gaps in their content validity and/or psychometric properties. These findings suggest the need for further testing/refinement of existing tools, and the opportunity to use other instruments alongside those most frequently used (e.g., ALSFRS-R) to comprehensively capture the patient experience of ALS in future clinical trial and real-world studies.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of Identifying Acute Nontraumatic Intracerebral Hemorrhage Events Using Diagnostic Coding Among Veterans with Mild Cognitive Impairment or Alzheimer's Dementia.","authors":"Dan Berlowitz, Ying Wang, Joel Reisman, Donald Miller, Peter J Morin, Vanesa Carlota Andreu Arasa, Brant Mittler, Raymond Zhang, Amir Abbas Tahami Monfared, Michael Irizarry, Quanwu Zhang, Weiming Xia","doi":"10.1007/s40120-025-00746-6","DOIUrl":"https://doi.org/10.1007/s40120-025-00746-6","url":null,"abstract":"<p><strong>Introduction: </strong>Based on manual review of clinical notes of using the International Classification of Diseases, Tenth Revision coding, we evaluated the feasibility and validity for monitoring, recording, and reporting intracerebral hemorrhage (ICH) events in patients with all-cause mild cognitive impairment or Alzheimer's dementia including, but not limited to, patients eligible for anti-amyloid therapy.</p><p><strong>Methods: </strong>Principal and first-position hospital discharge codes for ICH events for 200 patients were identified from the Veterans Affairs Health System structured administrative database. Clinician manual review of discharge summary notes assessed and confirmed the presence of coded events. Available documentation of bleed locations was further reviewed, and the extent of event adjudication for potential etiology was assessed. Additionally, 25 acute ICH cases were randomly identified by reviewing discharge notes to confirm corresponding diagnostic code-based reporting.</p><p><strong>Results: </strong>Of the 200 identified patients, 161 with acute ICH events were confirmed, resulting in a positive predictive value (PPV) of 80.5% for ICH event presence identified by diagnostic coding. Bleed locations were described for 151 of 161 patients with confirmed events. Of 110 cases whose diagnostic codes indicated an event location, 79 had location descriptions in discharge summaries that were consistent with the coding (PPV = 71.8%). Possible etiology was described in 56/161 patients' discharge summaries. Among the 25 acute ICH cases identified from discharge notes, 8 had corresponding ICH diagnostic codes.</p><p><strong>Conclusion: </strong>This study supports the feasibility and validity of the ICD-10 coding system for monitoring, recording, and reporting ICH event presence. When location is specified in the codes, the ICD-10 coding has an acceptable PPV. Overall, the current diagnostic coding system provides a reasonable framework for initial reporting and may allow for only limited inference of etiology such as differentiating nontraumatic versus traumatic events. Coding accuracy for ICH can be expected to further improve with the availability of guidelines, training, and standardization across clinical practices.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review.","authors":"Juliana West, Maggie Li, Sabrina Wong, Gia Han Le, Kayla M Teopiz, Kyle Valentino, Christine E Dri, Roger S McIntyre","doi":"10.1007/s40120-025-00724-y","DOIUrl":"10.1007/s40120-025-00724-y","url":null,"abstract":"<p><strong>Introduction: </strong>Glucagon-like peptide-1 (GLP-1) is an incretin hormone that modulates glucose metabolism and insulin secretion. Recent translational and clinical research has evaluated the effects of GLP-1 receptor agonists (GLP-1 RAs), a class of drugs that mimic the action of native GLP-1 in the central nervous system (CNS). In addition to the efficacy of GLP-1 for the treatment of diabetes mellitus and obesity, preliminary evidence indicates GLP-1s have neuroprotective, therapeutic, and disease modification effects for select neurodegenerative disorders (e.g. Parkinson's disease, Alzheimer's disease). Among the available GLP-1 RAs, relatively few have been shown to be CNS penetrant. This article synthesizes extant literature reporting on CNS penetrants of GLP-1 RAs as proxied by brain imaging studies. Where available, studies that reported on the bioavailability of GLP-1 RAs in the CNS were identified.</p><p><strong>Methods: </strong>A comprehensive search of PubMed, Ovid, and Web of Science from database inception to July 2024 was conducted. Inclusion criteria were English language publications with no date restrictions, preclinical and clinical studies with participants aged 18-80 and studies which focused on GLP-1 RAs including: \"Semaglutide\" or \"Ozempic\" or \"Rybelsus\" or \"Wegovy\" or \"Dulaglutide\" or \"Trulicity\" or \"Exenatide\" or \"Byetta\" or \"Bydureon\" or \"Liraglutide\" or \"Lixisenatide\" or \"Tirzepatide\" or \"Mounjaro\" or \"Zepbound\" or \"Bydureon BCise\" or \"Adlyxin\" or \"Victoza\" or \"Saxenda\".</p><p><strong>Results: </strong>We identified 14 studies that were included in this synthesis. Preclinical studies suggest that select GLP-1 RAs cross the blood-brain barrier (BBB) (i.e. liraglutide, semaglutide, and exenatide). Replicated evidence suggests that CNS penetration of GLP-1 RAs can be proxied by reported effects of GLP-1 RAs on brain connectivity in human participants.</p><p><strong>Conclusion: </strong> Preclinical studies indicate that select GLP-1 RAs are CNS penetrant; whether GLP-1 RAs reproducibly engage neural targets hypothesized to subserve dimensions of psychopathology (e.g., general cognitive functions) remains incompletely characterized.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Podcast on the Rhythms of Healing: Patient and Physician Insights on Art, Music, Dance Therapy and Creativity in Parkinson's Disease.","authors":"Caroline Cowan, Richard Walker","doi":"10.1007/s40120-024-00688-5","DOIUrl":"10.1007/s40120-024-00688-5","url":null,"abstract":"<p><p>This is an outline for a podcast. Parkinson's Disease (PD) is a progressive neurodegenerative disease in which there is increasing loss of dopamine neurones from the basal ganglia (Simon et al. Clin Geriatr Med. 36(1):1-12). Motor symptoms, which are usually asymmetrical, include resting tremor, rigidity, bradykinesia (slow movement) and, usually later on, postural instability. PD is primarily a clinical diagnosis although a DaTscan, which if positive shows asymmetrical loss of dopamine uptake in the basal ganglia, is helpful in cases of doubt (Tsang and Walker J Neurol 270(5):2550-2558).</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"429-436"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Objective Tool to Assess Tremor Reveals Unilateral Focused Ultrasound Improves Tremor Bilaterally.","authors":"Vered Aharonson, Teddy Lazebnik, Alon Sinai, Maria Nassar, Inna Senderova, Marius Constantinescu, Lior Lev Tov, Ilana Schlesinger","doi":"10.1007/s40120-024-00705-7","DOIUrl":"10.1007/s40120-024-00705-7","url":null,"abstract":"<p><strong>Background: </strong>Tremor in essential tremor and in tremor-dominant Parkinson's disease is assessed by subjective observations in patients undergoing focused ultrasound thalamotomy, a minimally invasive procedure intended to alleviate tremor in these patients.</p><p><strong>Objective: </strong>To develop an objective tool for tremor analysis to be used before and after focused ultrasound thalamotomy treatment in the treated hand (contralateral to ablation) and non-treated (ipsilateral to ablation).</p><p><strong>Methods: </strong>Using image processing and signal processing that utilized images of a Archimedes spiral drawing, we created a tool to analyze tremor. First, we showed that the proposed tool reproduces known clinical dynamics on the treated hand, and then we used it to evaluate the clinical dynamics on the non-treated hand.</p><p><strong>Results: </strong>Using the tool we developed, we were able to demonstrate a significant reduction in tremor following focused ultrasound thalamotomy among 132 essential tremor and 26 tremor-dominant Parkinson's disease patients in the treated hand using drawings of Archimedes spirals up to 1 year following the procedure. Thus, we reproduced known clinical data and therefore validated the proposed tool. In addition, we were able to demonstrate a significant improvement in the non-treated hand as well as a significant deterioration in the efficacy of focused ultrasound thalamotomy over time.</p><p><strong>Conclusion: </strong>Our objective method, which incorporated image processing and signal processing, provided a quantitative measure of tremor reduction following focused ultrasound thalamotomy. It demonstrated significant improvement in tremors in the treated and non-treated hands following focused ultrasound thalamotomy as well as deterioration in the efficacy of treatment over time. If replicated in other studies, this method may complement current subjective assessments.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"565-574"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in Surgical Therapies for Drug-Resistant Epilepsy: A Paradigm Shift towards Precision Care.","authors":"Chen Zhong, Kang Yang, Nianhua Wang, Liang Yang, Zhuanyi Yang, Lixin Xu, Jun Wang, Longbo Zhang","doi":"10.1007/s40120-025-00710-4","DOIUrl":"10.1007/s40120-025-00710-4","url":null,"abstract":"<p><p>Epilepsy, a prevalent neurological disorder characterized by recurrent seizures, affects millions worldwide, with a significant proportion resistant to pharmacological treatments. Surgical interventions have emerged as pivotal in managing drug-resistant epilepsy (DRE), aiming to reduce seizure frequency or achieve seizure freedom. Traditional resective surgeries have evolved with technological advances, enhancing precision and safety. Neurostimulation techniques, such as responsive neurostimulation (RNS) and deep brain stimulation (DBS), now provide personalized, real-time seizure management, offering alternatives to traditional surgery. Minimally invasive ablative methods, such as laser interstitial thermal therapy (LITT) and Magnetic Resonance-guided Focused Ultrasound (MRgFUS), allow for targeted destruction of epileptogenic tissue with reduced risks and faster recovery times. The use of stereo-electroencephalography (SEEG) and robotic assistance has further refined surgical precision, enhancing outcomes. These advancements mark a paradigm shift towards precision medicine in epilepsy care, promising improved seizure management and quality of life for patients globally. This review outlines the latest innovations in epilepsy surgery, emphasizing their mechanisms and clinical implications to improve outcomes for patients with DRE.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"467-490"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Generated Data as Indicators of Impact of Multidisciplinary and Multi-stakeholder Health Care Systems, in the Age of Personalised Medicine.","authors":"Paola Zaratin, Per Soelberg Sørensen, Óscar Fernández, Giancarlo Comi","doi":"10.1007/s40120-024-00706-6","DOIUrl":"10.1007/s40120-024-00706-6","url":null,"abstract":"<p><p>Using the case study of the Multiple Sclerosis Care Unit Initiative launched by the European Charcot Foundation, we discuss the need to evaluate the impact of multidisciplinary and multi-stakeholder healthcare systems on patient-reported experience and outcomes for the programming and monitoring of brain and neurodegenerative diseases in Europe and beyond. The multiple sclerosis (MS) case study presented in this paper highlights the role of patient-generated data as indicators of the impact of value-based healthcare (VBHC) for all the different neurological diseases whose prodromal symptoms are the first signs of disease progression and therefore instrumental markers for preventive treatments to preserve brain health. A holistic approach to the treatment of MS plays a crucial role in the inclusion and scientific meaning of the patient's perspective in terms of patient-reported dimension and patient-generated health data (PGHD).</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"437-446"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}